Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK2 V617F JAK2 Y931C |
| Therapy | Ruxolitinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 V617F and Y931C was resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 Y931C | hematologic cancer | resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964). | 21926964 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21926964) | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. | Full reference... |
| (39091915) | Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms. | Full reference... |